Pancreatic cancer is a deadly disease that is typically refractory to even the most aggressive cytotoxic chemotherapy regimens. Recent advances in chemotherapy for pancreatic cancer have led to some improvement in response rates;however, the majority of patients still do not substantially benefit from therapy. Responses to chemotherapy commonly occur through apoptosis, a form of programmed cell death. Our goal is to identify genes whose loss of function enhances sensitivity of pancreatic cancer cells to apoptosis. BH3 profiling is a well-characterized upstream measurement of the apoptotic sensitivity or "priming" of cancer cells and has been shown to correlate with response to chemotherapy and disease prognosis in certain cancer types. We will utilize a novel screening approach called RNAi-BH3 Screening (RiB Screening) that combines loss-of-function genetic screening using pooled lentivirally delivered shRNAs with the technology of BH3 profiling. In this approach, we will identify genes whose knockdown results in enhanced priming for apoptosis across several pancreatic cell lines. Based on this loss of function genetic screen, we will attempt to identify known small molecules targeting these genes, and determine whether they alter apoptotic priming and chemosensitivity. Finally, we propose to evaluate potential clinical utility of identified genes or small molecules by determining their effect on BH3 Profiles and chemosensitivity in fresh patient-derived pancreatic cancer samples. The successful identification of such genes and small molecules will not only improve our understanding of chemotherapeutic response, but could also serve as novel biomarkers or therapeutic targets.

Public Health Relevance

This proposal outlines RiB Screening - a novel approach to identify genes that make pancreatic cancer cells more sensitive to conventional chemotherapy. This approach will identify novel regulators of cancer cell death and could identify new drug targets or small molecules that could be combined with cytotoxic chemotherapy to improve clinical outcomes.

Agency
National Institute of Health (NIH)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA188858-01
Application #
8770286
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Arya, Suresh
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02215